申请人:Lilly Industries Limited
公开号:US04892963A1
公开(公告)日:1990-01-09
Compounds of the following formula have pharmaceutical properties: ##STR1## in which X is R.sup.1 (HO)C.dbd.C(CN)--, R.sup.1 (CO)--CH(CN)-- or ##STR2## R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-6 alkyl, R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, hydroxy, halogen, nitro, cyano, carboxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halo-substituted C.sub.1-4 alkyl, halo-substituted C.sub.1-4 alkoxy, halo-substituted C.sub.1-4 alkylthio, C.sub.2-5 alkoxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, R'R"N- where R' and R" are each hydrogen or C.sub.1-4 alkyl R'"CONH-- where R'" is C.sub.1-4 alkyl, R.sup.6, R.sup.7 and R.sup.8 are each C.sub.1-6 alkyl, halo-substituted C.sub.1-6 alkyl or optionally substituted phenyl, or R.sup.6 and R.sup.7, together with the carbon atom to which they are attached, form a cycloalkyl group containing 3 to 7 carbon atoms, or R.sup.6, R.sup.7 and R.sup.8 together with the carbon atom to which they are attached, form a bicycloalkyl group containing 4 to 9 carbon atoms; and salts thereof.
以下化合物的分子式具有药理学特性:##STR1## 其中X为R.sup.1(HO)C.dbd.C(CN)--,R.sup.1(CO)--CH(CN)--或##STR2## R.sup.1和R.sup.2分别为氢或C.sub.1-6烷基,R.sup.3,R.sup.4和R.sup.5分别为氢,羟基,卤素,硝基,氰基,羧基,C.sub.1-4烷基,C.sub.1-4烷氧基,C.sub.1-4烷基硫基,卤代C.sub.1-4烷基,卤代C.sub.1-4烷氧基,卤代C.sub.1-4烷基硫基,C.sub.2-5烷氧羰基,可选取代苯基,可选取代苯氧基,R'R"N-其中R'和R"分别为氢或C.sub.1-4烷基,R'"CONH--其中R'"为C.sub.1-4烷基,R.sup.6,R.sup.7和R.sup.8分别为C.sub.1-6烷基,卤代C.sub.1-6烷基或可选取代苯基,或R.sup.6和R.sup.7与它们所附着的碳原子一起形成含有3到7个碳原子的环烷基,或R.sup.6,R.sup.7和R.sup.8与它们所附着的碳原子一起形成含有4到9个碳原子的双环烷基;及其盐。